RTW Biotech Opportunities Ltd

Declaration of Voting Results & Voting Rights Announcements • Sep 1, 2020

National Storage Mechanism | Additional information

RNS Number : 4661X

RTW Venture Fund Limited

01 September 2020

1 September 2020

RTW VENTURE FUND LIMITED

(the "Company")

TOTAL VOTING RIGHTS

In accordance with DTR 5.6.1R, as at 31 August 2020 the Company had 179,804,548 Ordinary Shares in issue, each with equal voting rights, and no shares held in Treasury.

This total voting rights figure can be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

RTW Investments, LP Stephanie Sirota, Chief Business Officer Alexandra Taracanova, PhD, Director of Investor Relations Julia Enright, Business Development Associate Ocorian Administration (Guernsey) Limited Kevin Smith	+1 (646) 343 9280 +44 (0) 1481 742 642
J.P. Morgan Cazenove                       William Simmonds Oliver Kenyon James Bouverat (Sales) Barclays Tom Swerling Andrew Tusa Ryan McCarthy	+44 (0)20 7742 4000 +44 (0)20 7623 2323

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVREANPPAAFEEEA